Boston Scientific announced the completion of its acquisition of Sadra Medical, USA, on 4 January 2011. The transaction follows the definitive merger agreement announced on 19 November 2010.
Under the terms of the agreement, Boston Scientific paid US$193 million to acquire the remaining 86% of Sadra Medical’s equity not already owned by Boston Scientific. The company expects the acquisition to be approximately one to two cents dilutive to US GAAP (Generally Accepted Accounting Principles) and adjusted earnings per share in 2011, 2012 and 2013, and accretive thereafter.
Sadra Medical is developing the first fully repositionable device for percutaneous aortic valve replacement to treat patients with severe aortic stenosis. The company recently completed a series of European feasibility studies for its Lotus Valve System, which consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. The low profile delivery system and introducer sheath are designed to enable accurate positioning, repositioning and retrieval at any time prior to release of the aortic valve implant.
“We are pleased to complete the acquisition of Sadra Medical, and we look forward to leveraging our clinical expertise and existing sales channels in the fast growing area of structural heart therapy,” said Ray Elliott, president and chief executive officer of Boston Scientific. “Structural heart therapy is one of our priority growth initiatives, and this acquisition marks another step towards realigning our portfolio through the execution of these initiatives.”
